Company Overview - Zhongsheng Pharmaceutical Co., Ltd. is located in Dongguan, Guangdong Province, established on December 31, 2001, and listed on December 11, 2009. The company focuses on the research, production, and sales of pharmaceuticals [1]. - The main business revenue composition includes: Traditional Chinese Medicine sales 53.03%, chemical drug sales 38.12%, Chinese medicinal materials and decoction pieces sales 6.13%, raw materials and intermediates sales 2.14%, and others 0.58% [1]. Financial Performance - For the first half of 2025, Zhongsheng Pharmaceutical achieved operating revenue of 1.3 billion yuan, a year-on-year decrease of 4.74%. However, the net profit attributable to the parent company was 188 million yuan, showing a significant year-on-year increase of 114.96% [2]. - Since its A-share listing, the company has distributed a total of 2.019 billion yuan in dividends, with 502 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 18, the stock price of Zhongsheng Pharmaceutical increased by 2.19%, reaching 20.54 yuan per share, with a total market capitalization of 17.458 billion yuan [1]. - The stock has seen a year-to-date increase of 71.88%, with a recent 5-day increase of 1.68%, a 20-day decrease of 8.95%, and a 60-day increase of 36.48% [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on July 29, where it recorded a net purchase of 181 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 89,900, a decrease of 1.32% from the previous period, with an average of 8,470 circulating shares per person, an increase of 1.33% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest with 9.1731 million shares, while other notable shareholders include Xingquan He Feng Mixed Fund and Xingquan Multi-Dimensional Value Mixed Fund, which have reduced their holdings [3].

截至6月30日，精华制药股东户数9.59万，较上期减少5.29%；人均流通股8492股，较上期增加5.58%。 2025年1月-6月，精华制药实现营业收入7.31亿元，同比增长1.54%；归母净利润1.31亿元，同比减少 3.54%。 分红方面，精华制药A股上市后累计派现5.33亿元。近三年，累计派现2.05亿元。 机构持仓方面，截止2025年6月30日，精华制药十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股852.83万股，相比上期增加447.88万股。汇添富中证中药ETF（560080）位居第四大流通 股东，持股267.52万股，相比上期减少24.37万股。中药ETF（159647）位居第十大流通股东，持股 107.16万股，为新进股东。南方中证1000ETF（512100）、华夏中证1000ETF（159845）、广发中证 1000ETF（560010）退出十大流通股东之列。 责任编辑：小浪快报 9月17日，精华制药跌0.40%，成交额6429.58万元。两融数据显示，当日精华制药获融资买入额710.15 万元，融资偿还726.46万元，融资净买入-16.31万元。截至9月17日，精华制 ...

9月17日，众生药业跌0.45%，成交额5.31亿元。两融数据显示，当日众生药业获融资买入额5095.26万 元，融资偿还5348.33万元，融资净买入-253.07万元。截至9月17日，众生药业融资融券余额合计5.53亿 元。 截至6月30日，众生药业股东户数8.99万，较上期减少1.32%；人均流通股8470股，较上期增加1.33%。 2025年1月-6月，众生药业实现营业收入13.00亿元，同比减少4.74%；归母净利润1.88亿元，同比增长 114.96%。 分红方面，众生药业A股上市后累计派现20.19亿元。近三年，累计派现5.02亿元。 融资方面，众生药业当日融资买入5095.26万元。当前融资余额5.51亿元，占流通市值的3.22%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，众生药业9月17日融券偿还2900.00股，融券卖出100.00股，按当日收盘价计算，卖出金额 2010.00元；融券余量13.00万股，融券余额261.30万元，超过近一年60%分位水平，处于较高位。 资料显示，广东众生药业股份有限公司位于广东省东莞市石龙镇西湖工业区信息产业园，成立日期2001 年12月 ...